Resistance Mutations in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib
Mutations at BTK C481 are the most common mutations seen in pooled trial data of chronic lymphocytic leukemia (CLL) patients on ibrutinib, leading to resistance and progressive disease (PD).